Petros Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
PTPI$0.07-46.5%Stored close · as of May 21, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit No. | | Description |
| 31.1* | | Rule 13a-14(a)/15d-14(a) Certification – Principal Executive Officer. |
| 31.2* | | Rule 13a-14(a)/15d-14(a) Certification – Principal Financial Officer. |
| 32.1** | | Section 1350 Certification – Principal Executive Officer. |
| 32.2** | | Section 1350 Certification – Principal Financial Officer. |
| 101 | | The following materials from Petros Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated Changes in Stockholders’ Equity/Members’ Capital; (iv) Consolidated Statements of Cash Flows; and (v) Notes to the Condensed Consolidated Financial Statements. |
| 104 | | Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101. |
| * | Filed herewith. |
|---|
| ** | Furnished herewith. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.